New hope for Tough-to-Treat skin cancer: trial tests custom immune cell therapy
NCT ID NCT07288112
Summary
This clinical trial is testing a personalized immunotherapy called DOC1021 for patients with melanoma that has stopped responding to standard treatments. The therapy uses a patient's own immune cells, loaded with markers from their tumor, to train the immune system to attack the cancer. The study will first check if the treatment is safe, then measure how well it shrinks tumors in up to 35 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Alabama
RECRUITINGBirmingham, Alabama, 35243, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.